The annual meeting of the European Hematology Association (EHA) has been one of the most important focal points for international haematology for many years. With more than 15,000 participants on site and online, the 2025 congress in Milan also offered a comprehensive overview of the latest studies, translational knowledge and clinical trends. There was a particular focus on multiple myeloma – a disease that has undergone a breathtaking transformation in recent years. While survival times were measured in months two decades ago, treatment today achieves disease control lasting several years in many cases. The EHA 2025 contributions clearly illustrated how dynamically the field is developing: Bispecific and trispecific antibodies, CAR-T cell therapies, real-world analyses, combination therapies and new biomarkers mark the path to a future that is likely to be characterized by precision and individualization.
You May Also Like
- "Survey of Health, Ageing and Retirement in Europe" (SHARE)
Analysis of polypharmacy in ≥65-year-olds
- New perspectives for clinics and research
Ageing, cellular senescence and Parkinson’s disease
- From early intervention to individualization
The new guidelines at a glance
- Artificial intelligence
Dr. ChatGPT: Large language models in everyday clinical practice
- Focus on prevention
Colorectal cancer screening – an update
- COPD therapy
Drug therapy – Update 2025
- From symptom to diagnosis
Oncology – Thymoma
- Patient-centered rounds in medicine